Pharma sector growth stays strong in FY27; margins to soften as costs escalate: Ind-Ra
Ind-Ra forecasts a strong beginning for the pharma sector in FY27, but cautions about margin pressure due to high costs, weak US demand, and stricter regulations. Despite this, the industry saw double-digit growth in the first quarter, driven by chronic therapies, new products, and the anti-diabetic segment.